Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$27.18 ▲ +0.78
(+2.96%)
MKT CAP: $1.38B • VOL: 270.8K
52W L $24 52W H $30
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$23
MEDIAN
$30
MEAN
$31
HIGH
$37
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LYCA TAPE
LYCA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $32.89 | $31.26 | 2025-02-14 | $24.73 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $34.25 | $32.07 | 2025-02-06 | $25.55 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $30.99 | $29.90 | 2025-01-29 | $26.09 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $27.72 | — | 2025-01-17 | $26.64 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $23.92 | $25.82 | 2025-01-09 | $24.19 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $32.34 | $28.27 | 2024-12-18 | $23.65 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $26.36 | $27.45 | 2024-12-04 | $25.28 | -4.3% | 48% | C |